Author: Mansoor Ahmed , Mohsin Ali, Seyed Abdulmajid Ayatollahi, Marjan Esfahanizadeh , Farzad Kobarfard, Ameer Hasan , Khalid Mohammed Khan and Syed Moazzam Haider
Publishing Date: 2018
Volume 31 Issue 2
During the past few decades the emergence of inorganic medicinal chemistry has been developed novel therapeutic agents. Researcher’s perseverance in this branch of chemistry has led them to explore further valuable chemical spaces by synthesizing metal complexes already known pharmacological agents for their potential use. However, it is in its early stage, this methodology has demonstrated metal complexes with better bioactivities than the parent ligand molecules. In this study, transition metal complexes of pyrazinamide (PZ), isoniazid (INH), fluconazole (FCZ), metformin (dimethylbiguanide, DMBG) and losartan potassium (LS-K) were selected to evaluate for their possible anti-platelets aggregation in the light of reports on divalent and trivalent cations like calcium, copper, manganese, magnesium, and cadmium may influence the process of thrombocytic activity and aggregation. The required evaluation was carried out on human plasma through an APACT 4004 platelet aggregation analyzer. Arachidonic acid (ADP) was used to gauge any alteration in platelet shape and aggregation process. The parent drugs showed some antiplatelets aggregation, however, their metal complexes demonstrated better efficacy.
Keywords: Synthesis, Transition metal complexes, clinically in use molecules, Anti-platelets aggregation, Thrombosis.